These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22859825)

  • 21. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
    Mugo N; Eckert LO; Odero L; Gakuo S; Ngure K; Celum C; Baeten JM; Barnabas RV; Wald A
    Vaccine; 2021 Jul; 39(33):4751-4758. PubMed ID: 33485644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.
    Scherpenisse M; Mollers M; Schepp RM; Meijer CJ; de Melker HE; Berbers GA; van der Klis FR
    Hum Vaccin Immunother; 2013 Feb; 9(2):314-21. PubMed ID: 23149693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.
    Rotstein Grein IH; Pinto NF; Lobo A; Groot N; Sztajnbok F; da Silva CAA; Paim Marques LB; Appenzeller S; Islabão AG; Magalhães CS; de Almeida RG; Bica B; Fraga M; da Fraga ACM; Dos Santos MC; Robazzi T; Terreri MTR; Bandeira M; Pasmans H; Schepp R; van der Klis F; de Roock S; Wulffraat N; Pileggi G
    Lupus; 2020 Jul; 29(8):934-942. PubMed ID: 32501172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
    PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
    Mikamo H; Yamagishi Y; Murata S; Yokokawa R; Han SR; Wakana A; Sawata M; Tanaka Y
    Vaccine; 2019 Mar; 37(12):1651-1658. PubMed ID: 30797638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
    LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
    Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis.
    Bissett SL; Godi A; Jit M; Beddows S
    Vaccine; 2017 Jul; 35(32):3922-3929. PubMed ID: 28633892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
    Huang Z; He J; Su J; Ou Z; Liu G; Fu R; Shou Q; Zheng M; Group T; Luxembourg A; Liao X; Zhang J
    Vaccine; 2021 Jan; 39(4):760-766. PubMed ID: 33239228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
    Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
    J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.
    Rowhani-Rahbar A; Alvarez FB; Bryan JT; Hughes JP; Hawes SE; Weiss NS; Koutsky LA
    J Clin Virol; 2012 Mar; 53(3):239-43. PubMed ID: 22209292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth.
    Moscicki AB; Karalius B; Tassiopoulos K; Yao TJ; Jacobson DL; Patel K; Purswani M; Seage GR;
    Clin Infect Dis; 2019 Sep; 69(7):1183-1191. PubMed ID: 30927547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
    Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques.
    Wang Y; Liu Y; Liang S; Yin F; Zhang H; Liu Y
    Papillomavirus Res; 2020 Dec; 10():100209. PubMed ID: 33197649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
    Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brief Report: Persistence of Non-Vaccine Oncogenic HPV Genotypes in Quadrivalent HPV-Vaccinated Women Living With HIV.
    McClymont E; Coutlée F; Lee M; Albert A; Raboud J; Walmsley S; Lipsky N; Loutfy M; Trottier S; Smaill F; Klein MB; Yudin MH; Harris M; Wobeser W; Bitnun A; Samson L; Money D;
    J Acquir Immune Defic Syndr; 2020 Mar; 83(3):230-234. PubMed ID: 31917750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
    Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
    Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.
    Karanam B; Gambhira R; Peng S; Jagu S; Kim DJ; Ketner GW; Stern PL; Adams RJ; Roden RB
    Vaccine; 2009 Feb; 27(7):1040-9. PubMed ID: 19095032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.